Breaking News Instant updates and real-time market news.

PTC

PTC

$66.70

1.41 (2.16%)

, ESIO

Electro Scientific

$22.01

1.91 (9.50%)

17:28
01/17/18
01/17
17:28
01/17/18
17:28

On The Fly: After Hours Movers

UP AFTER EARNINGS: PTC (PTC), up 7.2%. ALSO HIGHER: Electro Scientific (ESIO), up 23.4% after it reported preliminary Q3 results... Neothetics (NEOT), up 12.6% after closing its merger with Evofem. DOWN AFTER EARNINGS: Plexus (PLXS), down 6.7%... Alcoa (AA), down 5.8%... Sallie Mae (SLM), down 4.3%. ALSO LOWER: Arrowhead (ARWR), down 9.8% after it filed to sell common stock... Paratek Pharmaceuticals (PRTK), down 8.9% after it filed to sell $50M in common stock... Innovative Industrial Properties (IIPR), down 4.2% after it filed to sell 1M shares of common stock... Eagle Point Credit (ECC), down 4% after it filed to sell 1.75M shares of common stock... Agios Pharmaceuticals (AGIO), down 2% after it filed to sell $400M in common stock.

PTC

PTC

$66.70

1.41 (2.16%)

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

NEOT

Neothetics

$1.92

0.0793 (4.31%)

PLXS

Plexus

$64.36

0.59 (0.93%)

AA

Alcoa

$56.99

0.75 (1.33%)

SLM

Sallie Mae

$11.49

0.02 (0.17%)

ARWR

Arrowhead

$5.72

0.12 (2.14%)

PRTK

Paratek Pharmaceuticals

$17.68

-0.075 (-0.42%)

IIPR

Innovative Industrial Properties

$31.30

-2.49 (-7.37%)

ECC

Eagle Point Credit

$19.13

-0.39 (-2.00%)

AGIO

Agios Pharmaceuticals

$70.33

1.53 (2.22%)

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 07

    Feb

  • 26

    Feb

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

PTC PTC
$66.70

1.41 (2.16%)

01/02/18
KEYB
01/02/18
NO CHANGE
KEYB
Shopify, PTC among favorite ideas in vertical software, says KeyBanc
KeyBanc analyst Monika Garg expects vertical software companies to outperform in 2018 due to their deep vertical moats, which can help derive high market share and margins. The analyst's favorite ideas for 2018 are Shopify (SHOP), PTC (PTC), 2U (TWOU), and RealPage (RP.) Due to headwinds for brick-and-mortar retailers, she remains cautious on Manhattan Associates (MANH), SPS Commerce (SPSC), ChannelAdvisor (ECOM), and CommerceHub (CHUBA).
12/12/17
JPMS
12/12/17
DOWNGRADE
Target $68
JPMS
Neutral
PTC downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Sterling Auty downgraded PTC to Neutral with an unchanged price target of $68 in conjunction with his 2018 annual outlook for Software Technology. The analyst does not expect the "exceptional performance" in Software during 2017 to repeat in 2018. As such, he's moderating his bullish outlook into next year.
11/13/17
JPMS
11/13/17
NO CHANGE
JPMS
Overweight
GE comments on digital encouraging for PTC, says JPMorgan
General Electric's (GE) investor day presentation suggests the company will continue to build out its digital capabilities, but in a focused way, JPMorgan analyst Sterling Auty tells investors in a research note. This likely means more focus on partnerships in the near term, which could help PTC (PTC) given its growing presence within the Predix platform, the analyst contends. He finds GE's comments on encouraging for Overweight-rated PTC.
11/06/17
BOFA
11/06/17
INITIATION
Target $60
BOFA
Underperform
PTC initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst Shankar Subramanian initiated PTC with an Underperform and $60 price target. The analyst said competition by industrial competitors is increasing and checks indicate the core business subscription transition could be difficult.
ESIO Electro Scientific
$22.01

1.91 (9.50%)

09/18/17
LSCM
09/18/17
NO CHANGE
Target $14.5
LSCM
Buy
Electro Scientific price target raised to $14.50 from $10.50 at Lake Street
Lake Street analyst Jaeson Schmidt earlier today raised his price target for Electro Scientific Industries shares to $14.50 and reiterated a Buy rating on the name. After meeting with management, Schmidt believes the company's turnaround is on track and its order trends are strong. Some investors are still underestimating the potential earnings leverage in the model, even after the last two quarterly beats, the analyst told investors in a research note.
11/02/17
DADA
11/02/17
NO CHANGE
Target $25
DADA
Buy
Electro Scientific price target raised to $25 from $15 at DA Davidson
DA Davidson analyst Thomas Diffely raised his price target on Electro Scientific to $25 and kept his Buy rating following Q2 earnings. Diffely says the book-to-bill metrics of the latest quarter were so strong that the management forecast the company's "lofty" revenue to extend into the March quarter in addition to the seasonally-weak December period. The analyst is raising his FY18 EPS forecast for Electro Scientific to $1.45 from 90c, noting that the trends of high demand for the company's solutions from the handset makers should only strengthen in years ahead.
11/02/17
LSCM
11/02/17
NO CHANGE
Target $22
LSCM
Buy
Electro Scientific price target raised to $22 from $14.50 at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for Electro Scientific Industries to $22 saying the company's momentum is even stronger than he thought. Following the Q3 results and "massive upside" to guidance, the analyst keeps a Buy rating on the shares.
12/01/17
LSCM
12/01/17
NO CHANGE
Target $27
LSCM
Buy
Electro Scientific price target raised to $27 from $22 at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for Electro Scientific to $27 saying recent channel checks indicate the company's momentum remains strong. The tailwinds in the flex circuit market that drove fiscal 2018 should continue to benefit the company's PCB product, Schmidt tells investors in a research note. The analyst recommends using the recent weakness in Electro Scientific shares as a buying opportunity. He reiterates a Buy rating on the name.
NEOT Neothetics
$1.92

0.0793 (4.31%)

PLXS Plexus
$64.36

0.59 (0.93%)

10/10/17
JPMS
10/10/17
DOWNGRADE
Target $62
JPMS
Neutral
Plexus downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded Plexus (PLXS) to Neutral saying the shares are close to fair value after rallying 20% from a late-August low. The analyst recommends investors look at Flex (FLEX) and TTM Technologies (TTMI) as alternatives. He keeps a $62 price target for Plexus shares.
01/08/18
LBOW
01/08/18
UPGRADE
LBOW
Buy
Plexus upgraded to Buy from Neutral at Longbow
01/08/18
01/08/18
UPGRADE
Target $72

Buy
Plexus upgraded to Buy on repatriation options at Longbow
As previously reported, Longbow analyst Shawn Harrison upgraded Plexus to Buy from Neutral, estimating the company will have $550M of repatriated cash for deployment and stating that it has multiple accretive ways to use this cash, including more buybacks, debt paydown or the initiation of a dividend. Harrison set a $72 price target on Plexus shares.
08/28/17
JPMS
08/28/17
UPGRADE
Target $62
JPMS
Overweight
Plexus upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster upgraded Plexus to Overweight citing valuation with the shares down 10% since July 20. The analyst sees a good entry point at current share levels and keeps a $62 price target for the stock.
AA Alcoa
$56.99

0.75 (1.33%)

11/29/17
SBSH
11/29/17
NO CHANGE
Target $55
SBSH
Buy
Alcoa to benefit little from aluminum trade actions, says Citi
The U.S. Department of Commerce yesterday self-initiated antidumping and countervailing duty investigations of common alloy aluminum sheet from China, Citi analyst Alexander Hacking tells investors in a research note. The analyst sees "very limited" direct benefit to Alcoa given that can sheet is excluded. Hacking also sees "limited positive read through" for the steel sector, since the action exclusively targets China. The analyst keeps a Buy rating on Alcoa with a $55 price target.
12/20/17
FBCO
12/20/17
UPGRADE
Target $61
FBCO
Outperform
Credit Suisse upgrades Alcoa ahead of aluminum market tightening
Credit Suisse analyst Curt Woodworth upgraded Alcoa to Outperform from Neutral and raised his price target for the shares to $61 from $42. The aluminum market is set to tighten into 2018, as structural policies in China address captive coal plants and illegal smelters remain intact, Woodworth tells investors in a research note. The analyst sees downstream demand "sharply" recovering in Q1 of 2018 and views Alcoa's valuation as compelling at current levels. The company is set to become a capital return story with $525M of potential capital to be returned in 2018 via dividends or buybacks, Woodworth contends. Further, the analyst thinks Alcoa could be added to the S&P 500 index in 2018.
12/20/17
FBCO
12/20/17
UPGRADE
FBCO
Outperform
Alcoa upgraded to Outperform from Neutral at Credit Suisse
01/11/18
SBSH
01/11/18
NO CHANGE
Target $65
SBSH
Buy
Alcoa price target raised to $65 from $53 at Citi
Citi analyst Alexander Hacking raised his price target for Alcoa to $65 on the belief that "sustainably higher" aluminum prices, supported by the cost curve, will re-rate multiples higher. The analyst believes the stock looks inexpensive and he keeps a Buy rating on the shares.
SLM Sallie Mae
$11.49

0.02 (0.17%)

12/12/17
FBCO
12/12/17
NO CHANGE
FBCO
Outperform
Synchrony, Discover among biggest beneficiaries of tax reform, says Credit Suisse
Credit Suisse analyst Moshe Orenbuch views tax reform as highly beneficial to U.S. consumer finance companies as most companies are full U.S. tax payers and any increases in consumer confidence from more cash flow could lead to more consumer borrowing, driving faster revenue growth and improved credit quality. His favorites to benefit from tax reform are Synchrony (SYF), Discover (DFS), OneMain (OMF), CIT Group (CIT), Santander Consumer (SC), Sallie Mae (SLM), and Air Lease (AL).
01/08/18
OPCO
01/08/18
INITIATION
Target $17
OPCO
Outperform
Sallie Mae initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ben Chittenden started Sallie Mae with an Outperform rating and $17 price target.
01/08/18
OPCO
01/08/18
INITIATION
Target $17
OPCO
Outperform
Sallie Mae initiated with an Outperform at Oppenheimer
As reported earlier, Oppenheimer analyst Ben Chittenden initiated Sallie Mae with an Outperform rating and a price target of $17, citing a "secular mix shift away from Federal funding of educational tuition and toward private lenders" where the company has a leading market share. The analyst says Sallie Mae will continue to benefit from better efficiency ratio, estimating mid-30s % versus "40% range" currently.
01/08/18
OPCO
01/08/18
INITIATION
OPCO
Perform
Navient initiated with a Perform at Oppenheimer
As reported earlier, Oppenheimer analyst Ben Chittenden initiated Navient (NAVI) with a Perform rating. Chittenden says the bulk of the company revenue still comes from its legacy loan book and private student loan portfolio, and both of those segments are under pressure. The analyst adds that 2019 could mark a key turning point, when Navient's non-compete agreement with Sallie Mae (SLM) expires, allowing it to originate private student loans again.
ARWR Arrowhead
$5.72

0.12 (2.14%)

01/05/18
RILY
01/05/18
INITIATION
Target $3
RILY
Neutral
Arrowhead initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Arrowhead Pharmaceuticals with a Neutral rating and $3 price target.
09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
William Blair upgrades Arrowhead with $6 fair value estimate
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform from Market Perform and raised her fair value estimate for the shares to $6 from $2. The stock closed Friday up 51c to $3.30. Last week's R&D day revealed the TRiM platform for developing novel RNA interference medicines and promised five investigational new drug or clinical trial application filings in 2018, Xu tells investors in a research note. The analyst highlights "versatility" of the company's TRiM platform for designing decorated RNAi drugs.
09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
Arrowhead upgraded to Outperform from Market Perform at William Blair
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform saying the company's analyst day highlighted a "broad" pipeline.
11/27/17
PIPR
11/27/17
UPGRADE
Target $5.5
PIPR
Overweight
Arrowhead upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff upgraded Arrowhead Pharmaceuticals to Overweight and raised his price target for the shares to $5.50 from $3. The shares closed Friday up 6c to $3.70. The company intends to file five Clinical Trial Applications on subcutaneous targeted RNAi molecules in 2018, Tenthoff tells investors in a research note. The analyst looks for Arrowhead to create value by generating first in man TRiM clinical data and potentially signing new partnerships.
PRTK Paratek Pharmaceuticals
$17.68

-0.075 (-0.42%)

07/20/17
CANT
07/20/17
NO CHANGE
Target $50
CANT
Overweight
Paratek Pharmaceuticals recent selloff overdone, says Cantor
Cantor Fitzgerald analyst Louise Chen says the two day selloff in shares of Paratek Pharmaceuticals (PRTK) after "positive and competitive" data from the company's OASIS-2 trials is overdone. The issues experienced by Cempra's (CEMP) community antibiotic product are entirely product-specific and not a read-through to Paratek, Chen told investors last night in a research note. She believes Paratek will be able to market Omadacycline effectively if it is approved and keeps an Overweight rating on the shares with a $50 price target.
07/18/17
LEER
07/18/17
NO CHANGE
Target $37
LEER
Outperform
Oral only skin study represents third positive Phase 3 for Paratek, says Leerink
Leerink analyst Paul Matteis notes that Paratek Pharmaceuticals announced positive Phase 3 results from its oral only omadacycline acute bacterial skin and skin structure infection Phase 3 trial, with the study showing statistical non-inferiority on all key clinical endpoints. With three positive Phase 3s, the analyst models a 90% probability of omadacycline approval, likely by late 2018 or early 2019. Matteis reiterates an Outperform rating and $37 price target on the shares.
07/18/17
HCWC
07/18/17
NO CHANGE
Target $43
HCWC
Buy
Paratek Pharmaceuticals price target raised to $43 from $36 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Paratek Pharmaceuticals to $43 after the company announced positive top-line results of its alloral Phase 3 trial of omadacycline for the treatment of acute bacterial skin and skin structure infections. The analyst sees higher rates of nausea and vomiting as having a negligible impact to omadacycline's commercial opportunity. He keeps a Buy rating on Paratek shares.
08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
IIPR Innovative Industrial Properties
$31.30

-2.49 (-7.37%)

ECC Eagle Point Credit
$19.13

-0.39 (-2.00%)

05/16/17
OPCO
05/16/17
INITIATION
Target $24
OPCO
Outperform
Eagle Point Credit initiated with an Outperform at Oppenheimer
Oppenheimer analyst Chris Kotowski started Eagle Point Credit with an Outperform rating and $24 price target.
09/25/17
LTCO
09/25/17
INITIATION
Target $20.5
LTCO
Buy
Eagle Point Credit initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Mickey Schleien started Eagle Point Credit with a Buy rating and $20.50 price target.
AGIO Agios Pharmaceuticals
$70.33

1.53 (2.22%)

08/02/17
08/02/17
UPGRADE
Target $80

Outperform
Agios Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Michael Schmidt upgraded Agios Pharmaceuticals to Outperform from Market Perform based on his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. The analyst also raised his price target on the shares to $80 from $50.
09/14/17
RBCM
09/14/17
INITIATION
Target $78
RBCM
Outperform
Agios Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Agios Pharmaceuticals with an Outperform and a $78 price target.
09/18/17
JPMS
09/18/17
NO CHANGE
Target $76
JPMS
Overweight
Agios Pharmaceuticals price target raised to $76 from $71 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Agios Pharmaceuticals to $76 after conducting a survey of 26 U.S. hematologists. The survey indicated there is broader awareness of Idhifa, "encouraging views" on its efficacy and "rapid uptake," Rama tells investors in a research note. The analyst reiterates an Overweight rating on Agios.
08/02/17
08/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei saying he expects "positive updates" on the company's pipeline that could improve investors' view on the company. 2. Royal Caribbean (RCL) upgraded to Neutral from Sell at Goldman Sachs with analyst Stephen Grambling citing "strong" leisure trends following the company's better than expected second quarter results. 3. Illumina (ILMN) upgraded to Equal-Weight from Underweight at First Analysis with analyst Joseph Munda saying concerns regarding sequencing overcapacity in the marketplace and the potential rate of adoption for NovaSeq are diminishing based on performance in the quarter. 4. Agios Pharmaceuticals (AGIO) upgraded to Outperform from Market Perform at Leerink with analyst Michael Schmidt citing his higher-level conviction regarding the commercial opportunity for its IDH inhibitors Idhifa and ivosidenib in acute myeloid leukemia following Idhifa FDA-approval and his recent checks indicating a high degree of enthusiasm for these agents in the physician community pointing to potential good initial uptake. 5. Sonoco Products (SON) upgraded to Hold from Sell at Vertical Research with analyst Chip Dillion citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CCB

Coastal Financial

$0.00

(0.00%)

21:11
07/17/18
07/17
21:11
07/17/18
21:11
Syndicate
Coastal Financial 2.85M share IPO priced at $14.50 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CRNX

Crinetics

$0.00

(0.00%)

21:08
07/17/18
07/17
21:08
07/17/18
21:08
Syndicate
Crinetics 6M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

NSTG

NanoString

$12.74

-2.36 (-15.63%)

21:07
07/17/18
07/17
21:07
07/17/18
21:07
Syndicate
NanoString 4M share Secondary priced at $12.50 »

JPMorgan and UBS acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 18

    Jul

ALV

Autoliv

$106.86

1.57 (1.49%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Autoliv rating change  »

Autoliv downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.71

3.58 (2.79%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

ABT

Abbott

$62.84

1.05 (1.70%)

, MS

Morgan Stanley

$49.20

0.29 (0.59%)

20:25
07/17/18
07/17
20:25
07/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$62.84

1.05 (1.70%)

MS

Morgan Stanley

$49.20

0.29 (0.59%)

USB

U.S. Bancorp

$51.29

-0.01 (-0.02%)

TXT

Textron

$66.81

0.14 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

ADTN

Adtran

$16.05

0.1 (0.63%)

20:14
07/17/18
07/17
20:14
07/17/18
20:14
Earnings
Adtran reports Q2 adjusted EPS (10c), two estimates (32c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

, ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

20:09
07/17/18
07/17
20:09
07/17/18
20:09
Hot Stocks
FS Bancorp to merge with Anchor Bancorp in $77M deal »

FS Bancorp (FSBW) and…

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$26.41

-1.19 (-4.31%)

20:06
07/17/18
07/17
20:06
07/17/18
20:06
Hot Stocks
Breaking Hot Stocks news story on Canopy Growth  »

Greenstar Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.95

0.94 (0.26%)

19:10
07/17/18
07/17
19:10
07/17/18
19:10
Hot Stocks
Boeing awarded $3.9B government contract »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MRTN

Marten Transport

$22.10

(0.00%)

, UAL

United Continental

$72.66

0.38 (0.53%)

19:03
07/17/18
07/17
19:03
07/17/18
19:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Martin…

MRTN

Marten Transport

$22.10

(0.00%)

UAL

United Continental

$72.66

0.38 (0.53%)

CSX

CSX

$64.42

0.46 (0.72%)

MLNX

Mellanox

$84.85

0.9 (1.07%)

IBKR

Interactive Brokers

$64.65

1.93 (3.08%)

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

TXN

Texas Instruments

$115.80

1.21 (1.06%)

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

CARA

Cara Therapeutics

$21.60

0.435 (2.06%)

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

TLYS

Tilly's

$15.35

0.21 (1.39%)

CLX

Clorox

$135.00

0.71 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 24

    Jul

  • 02

    Aug

  • 26

    Aug

  • 19

    Jul

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:38
07/17/18
07/17
18:38
07/17/18
18:38
Hot Stocks
BHP Billiton sees FY19 copper equivalent output broadly in line with FY18 »

Says expects to achieve…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:35
07/17/18
07/17
18:35
07/17/18
18:35
Hot Stocks
BHP Billiton reports Q4 petroleum production 49 MMBOE, down 6% »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$135.00

0.71 (0.53%)

18:31
07/17/18
07/17
18:31
07/17/18
18:31
Downgrade
Clorox rating change at Goldman Sachs »

Clorox downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

NCS

NCI Building

$20.70

0.15 (0.73%)

18:27
07/17/18
07/17
18:27
07/17/18
18:27
Hot Stocks
NCI Building Systems, Ply Gem Parent to combine in stock-for-stock merger »

NCI Building Systems and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

, AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

18:16
07/17/18
07/17
18:16
07/17/18
18:16
Earnings
America Movil reports Q2 operating profit MXN32.6M, up 4.8% from last year »

Reports Q2 revenue…

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

18:08
07/17/18
07/17
18:08
07/17/18
18:08
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Jul

  • 16

    Aug

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

, BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

18:06
07/17/18
07/17
18:06
07/17/18
18:06
Hot Stocks
Berkshire Hathaway amends share repurchase program »

The Board of Directors of…

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$60.10

-0.5 (-0.83%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Earnings
Pinnacle Financial reports Q2 EPS $1.15, consensus $1.14 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

CHDN

Churchill Downs

$304.60

1.1 (0.36%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Hot Stocks
Churchill Downs receives approval to increase historical racing machines »

Churchill Downs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CE

Celanese

$110.22

1.6 (1.47%)

18:01
07/17/18
07/17
18:01
07/17/18
18:01
Hot Stocks
Celanese announces acetic acid price increases in Asia »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

BLK

BlackRock

$504.89

1.14 (0.23%)

17:51
07/17/18
07/17
17:51
07/17/18
17:51
Hot Stocks
BlackRock raises quarterly dividend to $3.13 from $2.88 per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$12.47

0.57 (4.79%)

17:45
07/17/18
07/17
17:45
07/17/18
17:45
Conference/Events
Dicerna management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

, GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

17:44
07/17/18
07/17
17:44
07/17/18
17:44
Periodicals
Google faces record EU fine over Android dominance, FT reports »

Alphabet's Google…

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

BA

Boeing

$356.95

0.94 (0.26%)

17:39
07/17/18
07/17
17:39
07/17/18
17:39
Periodicals
Breaking Periodicals news story on Boeing »

Boeing awarded $3.9B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.